產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
400-999-210024小時(shí)服務(wù)熱線
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0178-1.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0178-2.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0178-3.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0178-4.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0178-5.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確)](/Public/upfile/pic/xbx/CL-0178-6.jpg)
![NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確)](/Public/upfile/pic/product/cell-line-new.jpg)
NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確)
貨號(hào)：CL-0178
規(guī)格：1×10?cells/T25培養(yǎng)瓶
價(jià)格： ￥2000
生長(zhǎng)培養(yǎng)基：RPMI-1640＋20% FBS＋10μg/mL Insulin＋1% P/S
產(chǎn)品概述
| 名稱 | NIH:OVCAR-3 [OVCAR3] (人卵巢癌細(xì)胞) (STR鑒定正確) |
| 別稱 | Ovcar-3; NIH:OVCAR-3; NIH:Ovcar-3; NIH:OVCAR3; NIH-OVCAR-3; NIHOVCAR3; OVCAR.3; OVCAR3; Ovcar3 |
| 種屬 | 人 |
| 生長(zhǎng)特性 | 貼壁細(xì)胞 |
| 細(xì)胞形態(tài) | 上皮細(xì)胞樣 |
| 凍存條件 | 凍存液：55% 基礎(chǔ)培養(yǎng)基+40%FBS+5%DMSO 溫度：液氮 |
| 培養(yǎng)方案A（默認(rèn)） |
生長(zhǎng)培養(yǎng)基:
培養(yǎng)條件:
氣相：空氣，95%；CO2，5%, 溫度：37℃
|
| 推薦傳代比例 | 1:2-1:4 |
| 推薦換液頻率 | 2-3次/周 |
| 背景描述 | NIH:OVCAR-3 [OVCAR3]細(xì)胞是由T·C·Hamilton在1982年建系，NIH:OVCAR-3 [OVCAR3]細(xì)胞取材于患進(jìn)行性卵巢腺癌病人的惡性腹水。在裸鼠皮下接種 1×10^7細(xì)胞，21天后全部成瘤。NIH:OVCAR-3 [OVCAR3]細(xì)胞是研究卵巢癌藥物抗性的一個(gè)合適的模型系統(tǒng)且由于存在激素受體，這對(duì)于激素治療的評(píng)估或許是有用的。 |
| 年齡（性別） | 女性；60歲 |
| 組織來(lái)源 | 卵巢腺癌 |
| 細(xì)胞類型 | 腫瘤細(xì)胞 |
| 腫瘤類型 | 卵巢癌細(xì)胞 |
| 生物安全等級(jí) | BSL-1 |
| 倍增時(shí)間 | ~35-64 hours |
| 致瘤性 | Yes, Forms colonies in soft agar.Yes, in nude mice inoculated subcutaneously with 1×10^7 cells (Tumors developed within 21 days at 100% frequency (5/5)). |
| 受體表達(dá)情況 | Androgen receptor, positive;estrogen receptor, positive;progesterone receptor, positive |
| 保藏機(jī)構(gòu) | ATCC; HTB-161 |
STR鑒定
-
STR位點(diǎn)信息
Amelogenin X CSF1PO 11,12 D2S1338 17,21 D3S1358 17,18 D5S818 11,12 D7S820 10 D8S1179 10,15 D13S317 12 D16S539 12 D18S51 13 D19S433 14,16.2 D21S11 29,31.2 FGA 21 PentaD 12,13 PentaE 7,13 TH01 9 TPOX 8 vWA 17 D6S1043 10,11 D12S391 19,22 D2S441 11,14 -
STR鑒定圖
-
參考文獻(xiàn)
-
Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression(2023/10/12)
作者：Yanan Pi, Qiushi Feng, Fusheng Sun
期刊：CELL DEATH AND DIFFERENTIATION
DOI：10.1038/s41418-023-01226-w
影響因子 ：12.400
引用產(chǎn)品：CL-0178
-
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer(2024/02/26)
作者：Weisong Li, Kai Zhang, Wenjun Wang
期刊：JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
DOI：10.1186/s13046-024-02981-5
影響因子 ：11.300
引用產(chǎn)品：CL-0178
-
MiR-337–3p suppresses proliferation of epithelial ovarian cancer bytargeting PIK3CA and PIK3CB(2019/10/17)
作者：Zhen Zhang, Luoyan Zhang, Bin Wang
期刊：Cancer Letters
DOI：10.1016/j.canlet.2019.10.021
影響因子 ：9.700
-
circ_0025033 promotes ovarian cancer development via regulating the hsa_miR-370-3p/SLC1A5 axis(2022/10/22)
作者：Huiping Ma, Shuyun Qu, Yao Zhai
期刊：CELLULAR & MOLECULAR BIOLOGY LETTERS
DOI：10.1186/s11658-022-00364-2
影響因子 ：8.300
-
A 19F NMR probe for the detection of β-galactosidase: simple structure with low molecular weight of 274.2, “turn-on” signal without the background, and good performance applicable in cancer cell line(2017/06/28)
作者：Jie Hu, Qiong Wu, Kai Cheng
期刊：J Mater Chem B
影響因子 ：7.571
引用產(chǎn)品：CL-0178
-
Isothiocyanate Iberin inhibits cell proliferation and induces cell apoptosis in the progression of ovarian cancer by mediating ROS accumulation and GPX1 expression(2021/06/17)
作者：Tingting Gong, Qian Guo, Xiao Li
期刊：Biomedicine & Pharmacotherapy
DOI：10.1016/j.biopha.2021.111533
影響因子 ：7.500
-
m6A methylation-mediated regulation of LncRNA MEG3 suppresses ovarian cancer progression through miR-885-5p and the VASH1 pathway(2024/01/29)
作者：Yan Li, Shenghan Lou, Jian Zhang
期刊：Journal of Translational Medicine
DOI：10.1186/s12967-024-04929-x
影響因子 ：7.400
引用產(chǎn)品：CL-0178
-
Dietary flavonoid tectochrysin synergistically enhances cisplatin sensitivity on ovarian cancer cells through targeting the CDK1/cyclin B1 pathway(2024/05/21)
作者：Shasha Liu, Yuling Guo, Feiya Jiang
期刊：Journal of Functional Foods
影響因子 ：5.600
引用產(chǎn)品：CL-0178
-
MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer(2021/04/17)
作者：Mengqi Deng, Di Wu, Yanqin Zhang
期刊：Gynecologic Oncology
DOI：10.1016/j.ygyno.2021.04.013
影響因子 ：4.700
-
Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53(2024/02/04)
作者：Zhaofeng Liu, Yifei Yang, Xiaohui Sun
期刊：MOLECULES
影響因子 ：4.600
引用產(chǎn)品：CL-0178
-
CircLNPEP promotes the progression of ovarian cancer through regulating miR-876-3p/ WNT5A axis(2021/08/31)
作者：Wenwen Wang, Weiwei Zhang, Hongjun Guo
期刊：Cell Cycle
DOI：10.1080/15384101.2021.1965723
影響因子 ：4.300
-
Knockdown of heat shock protein family D member 1 (HSPD1) promotes proliferation and migration of ovarian cancer cells via disrupting the stability of mitochondrial 3-oxoacyl-ACP synthase (OXSM)(2023/04/22)
作者：Yaoyun Duan, Juan Yu, Miaojuan Chen
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-023-01156-8
影響因子 ：4.000
-
CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells(2024/03/27)
作者：Qingsong Zhang, Rong Zhang, Yuzhi Li, Xiaojun Yang
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-024-01393-5
影響因子 ：4.000
引用產(chǎn)品：CL-0178
-
The CREB1/WNK1 axis promotes the tumorigenesis of ovarian cancer via regulating HIF-1(2024/04/08)
作者：Yifei Ma, Hui Zong, Pan Pan
期刊：EXPERIMENTAL CELL RESEARCH
DOI：10.1016/j.yexcr.2024.114006
影響因子 ：3.700
引用產(chǎn)品：CL-0178
-
MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo(2024/01/08)
作者：Yun Zhang, Fanglin Liu, Jindan Zheng
期刊：EXPERIMENTAL CELL RESEARCH
DOI：10.1016/j.yexcr.2024.113913
影響因子 ：3.700
引用產(chǎn)品：CL-0178
-
Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives(2023/11/27)
作者：Yan Li, Liang Meng, Ge Lou
期刊：CANCER BIOLOGY & THERAPY
DOI：10.1080/15384047.2023.2285817
影響因子 ：3.600
引用產(chǎn)品：CL-0178
-
Norcantharidin induces ferroptosis via the suppression of NRF2/HO?1 signaling in ovarian cancer cells(2022/08/25)
作者：Xiaoyan Zhu, Xiaohong Chen, Longshan Qiu
期刊：Oncology Letters
影響因子 ：2.900
-
ARID5B promoted the histone demethylation of SORBS2 and hampered the metastasis of ovarian cancer(2023/11/03)
作者：Yue Deng, Ying Dong, Lu Wu
期刊：PATHOLOGY RESEARCH AND PRACTICE
影響因子 ：2.800
引用產(chǎn)品：CL-0178
-
miR?638 suppresses proliferation by negatively regulating high mobility group?A1 in ovarian cancer cells(2021/9/20)
作者：Li Ma, Wei Zhang, Yaofeng Jin
期刊：Experimental and Therapeutic Medicine
影響因子 ：2.700
-
Down-regulation of DPP4 by TGFβ1/miR29a-3p inhibited proliferation and promoted migration of ovarian cancer cells(2023/10/31)
作者：Chong Liu, Zhaowei Gao, Yingqi Liu
期刊：Discover Oncology
DOI：10.1007/s12672-023-00815-y
影響因子 ：2.200
引用產(chǎn)品：CL-0178
-
MOB kinase activator 1A acts as an oncogene by targeting PI3K/AKT/mTOR in ovarian cancer(2023/06/14)
作者：Jian Lei, Jingying Xu, Min Hu
期刊：Discover Oncology
DOI：10.1007/s12672-023-00705-3
影響因子 ：2.200
引用產(chǎn)品：CL-0178
-
Circ_0021573 acts as a competing endogenous RNA to promote the malignant phenotypes of human ovarian cancer cells(2022/12/05)
作者：Lifang Liu, Bingkai Han, Lixia Liu
期刊：Reproductive Biology
DOI：10.1016/j.repbio.2022.100704
影響因子 ：2.100
引用產(chǎn)品：164210 164210-50 CL-0005 CL-0079 CL-0178 CL-0215 PB180120 PM150110
-
PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/β-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib(2022/09/05)
作者：Xiaocui Zhang, Meige Sun, Yisheng Jiao
期刊：Oxidative Medicine and Cellular Longevity
影響因子 ：0.000
引用產(chǎn)品：164210 164210-50 CL-0079 CL-0178 PM150110 PM150710
FAQs
Q：{{item.question}}
A：
產(chǎn)品資料
識(shí)別碼示意圖
娜胡文君.png "邱國(guó)娜/胡文君")
.png "梅文強(qiáng)")
